Lobe Sciences is a growth-oriented research, technology and services company focused on transformational medicines and devices. Based in Vancouver, BC, Lobe Sciences Ltd. creates value through acquisitions and development of assets, products and technologies by leveraging its scientific, engineering, branding and operation expertise supported by strong capital markets acumen.
Stock Performance
Lobe Sciences News 19 articles
- Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™
- Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™
- Lobe Sciences Announces Update
- Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise
- Lobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors
- Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors
- Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
- Lobe Sciences Congratulates Australia for Becoming the First Nation to Approve the Medicinal Use of Psilocybin and MDMA
- Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130
- Lobe Sciences to Present at MONEYSHOW VIRTUAL EXPO November 10, 2022
- Lobe Sciences Announces the Expansion of its Patent Portfolio with International Filings
- Lobe Sciences Announces Closing of Private Placement
- Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia
- Lobe Sciences Announces Update on Corporate Slide Deck Highlighting its Psilocin Compounds and Development Plans
- Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia
- Lobe Sciences Files Patent Application Covering the Preparation of Stable Psilocin Prodrugs and Analogues and their Uses Further Strengthening its Intellectual Property Portfolio
- Lobe Sciences Ltd. Announces Regulatory and Clinical Development Plans For 2022 and Early 2023
- Lobe Sciences and Clearway Global Enter into Agreement to Manage Lobe Science’s Global Regulatory and Development Strategy and Implementation
- Lobe Sciences and the World Boxing Association Announce Initiative Targeting mTBI and PTSD